Abstracts tagged "mycophenolate mofetil and systemic lupus erythematosus (SLE)"

Abstract Number: 2603 • 2017 ACR/ARHP Annual Meeting
Induction of Lupus Nephritisin in Real Situation: Cyclophosphamide or Mycophenolate Mofetil?
Gabriela Munhoz¹, Maira Lacerda¹, Michelle Lopes¹, Eduardo Ferreira Borba¹, Luciana Seguro² and Eloisa Bonfa³, ¹Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ³Rheumatology Divison, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Low-dose intravenous cyclophosphamide (Euro-lupus) and Mycophenolate mofetil (MMF) are well established in lupus nephritis induction therapy, but there are few studies comparing both treatments.…
Abstract Number: 2624 • 2017 ACR/ARHP Annual Meeting
A Renal Biopsy Should Not Delay Treatment Initiation in Suspected Lupus Nephritis
Astrid Baumann¹, Angela Pakozdi², Andrea Cove-Smith², Debasish Pyne², Michael Sheaff¹ and Ravindra Rajakariar², ¹Barts Lupus Centre, London, United Kingdom, ²Barts Lupus Centre, Barts Health NHS Trust, London, United Kingdom
Background/Purpose: Renal biopsies are considered the gold standard in diagnosing lupus nephritis (LN). ALMS (1), the largest randomized trial in LN, reported the non-inferiority of…
Abstract Number: 740 • 2016 ACR/ARHP Annual Meeting
Patient Adherence with Mycophenolate Mofetil Therapy in a Systemic Lupus Erythematosus Cohort: A Multi-Factorial Assessment
Maryam Ghaderi-Yeganeh¹, Ann Biehl², Zerai G. Manna³, Alice Fike⁴ and Sarfaraz Hasni³, ¹National Institutes of Arthritis, Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²Department of Pharmacy, National Institutes of Health Clinical Center, Bethesda, MD, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴Office of the Clinical Director, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
Background/Purpose: Lack of adherence to treatment recommendations is a serious confounder to assessment of treatment efficacy for systemic lupus erythematosus (SLE). Estimates of nonadherence with…
Abstract Number: 1824 • 2016 ACR/ARHP Annual Meeting
Mycophenolate Mofetil Use Associates with Unique Biologic Changes in B Cell and T Regulatory Cell Pathways in SLE Patients
Samantha Slight-Webb¹, Rufei Lu², Krista M. Bean¹, Holden T. Maecker³, Paul J. Utz⁴, Joel M. Guthridge⁵ and Judith A. James⁶, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁴Medicine, Stanford University School of Medicine, Stanford, CA, ⁵Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: The management of systemic lupus erythematosus (SLE) is complicated by a heterogeneous clinical presentation. Currently, mycophenolate mofetil (MMF) is a commonly used medication to…
Abstract Number: 724 • 2015 ACR/ARHP Annual Meeting
Mycophenolate Mofetil in Non-Renal Manifestations of Systemic Lupus Erythematosus. an Observational Cohort Study
Konstantinos Tselios¹, Dafna Gladman², Jiandong Su² and Murray Urowitz^2,3, ¹Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Mycophenolate mofetil (MMF), along with corticosteroids, is considered as the standard of care in lupus nephritis (LN); however, its efficacy in extra-renal manifestations of…
Abstract Number: 2937 • 2015 ACR/ARHP Annual Meeting
Treatment Patterns Differ Based on Age of Systemic Lupus Erythematosus Onset: A Comparison of Azathioprine and Mycophenolate on the Prevention of Lupus Nephritis
J. Madison Hyer¹, Bethany Wolf¹, Jim Oates², Gary S. Gilkeson³ and Diane L. Kamen², ¹Public Health Sciences, Medical University of South Carolina, Charleston, SC, ²Medicine, Medical University of South Carolina, Charleston, SC, ³Department of Rheumatology, Medical University of South Carolina, Charleston, SC
Background/Purpose: Lupus nephritis (LN) is a major cause of morbidity and mortality among patients with systemic lupus erythematous (SLE). Studies have demonstrated efficacy and safety…
Abstract Number: 1804 • 2013 ACR/ARHP Annual Meeting
Effect of Mycophenolate On the White Blood Cell Count and the Frequency of Infection in Systemic Lupus Erythematosus
Ananta Subedi¹, Hong Fang² and Michelle Petri², ¹Good Samaritan Hospital, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Leukopenia is a common manifestation of SLE. Addition of immunosuppressive therapy is of concern, in that it could worsen leukopenia; increase the risk of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].